IMM 124E

Drug Profile

IMM 124E

Alternative Names: Anti-LPS colostrum (Imm124-E) - Immuron; Bovine colostrum - Immuron; IMM-124E; IMM122-I

Latest Information Update: 26 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immuron
  • Developer Emory University; Hadassah Medical Organization; Immuron; La Trobe University; University of Melbourne; University of Zurich; Virginia Commonwealth University
  • Class Antibodies; Hepatoprotectants; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Alcoholic hepatitis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Preclinical Autistic disorder; Gastroenteritis
  • No development reported Metabolic syndrome

Most Recent Events

  • 24 Jul 2018 Immuron has patent protection for colostrum immunoglobulin preparation in Non-alcoholic steatohepatitis in Russia, Japan, Israel and South Korea
  • 24 Jul 2018 The European Patent Office grants a patent for colostrum immunoglobulin preparation in Non-alcoholic steatohepatitis
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top